FR15C0060I2 - Compositions pharmaceutiques comprenant un analogue d'un nucleotide destinees a la lyophilisation - Google Patents

Compositions pharmaceutiques comprenant un analogue d'un nucleotide destinees a la lyophilisation

Info

Publication number
FR15C0060I2
FR15C0060I2 FR15C0060C FR15C0060C FR15C0060I2 FR 15C0060 I2 FR15C0060 I2 FR 15C0060I2 FR 15C0060 C FR15C0060 C FR 15C0060C FR 15C0060 C FR15C0060 C FR 15C0060C FR 15C0060 I2 FR15C0060 I2 FR 15C0060I2
Authority
FR
France
Prior art keywords
lyophilization
intended
pharmaceutical compositions
nucleotide analogue
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0060C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of FR15C0060I1 publication Critical patent/FR15C0060I1/fr
Application granted granted Critical
Publication of FR15C0060I2 publication Critical patent/FR15C0060I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR15C0060C 1996-12-20 2015-09-07 Compositions pharmaceutiques comprenant un analogue d'un nucleotide destinees a la lyophilisation Active FR15C0060I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying

Publications (2)

Publication Number Publication Date
FR15C0060I1 FR15C0060I1 (cs) 2015-10-23
FR15C0060I2 true FR15C0060I2 (fr) 2016-04-22

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0060C Active FR15C0060I2 (fr) 1996-12-20 2015-09-07 Compositions pharmaceutiques comprenant un analogue d'un nucleotide destinees a la lyophilisation

Country Status (35)

Country Link
US (1) US6114313A (cs)
EP (1) EP1007094B1 (cs)
JP (1) JP4488538B2 (cs)
KR (1) KR100552880B1 (cs)
CN (1) CN1121875C (cs)
AR (1) AR010377A1 (cs)
AT (1) ATE221787T1 (cs)
AU (1) AU758857B2 (cs)
BR (1) BR9713974B1 (cs)
CA (1) CA2275153C (cs)
CZ (1) CZ300635B6 (cs)
DE (1) DE69714616T2 (cs)
DK (1) DK1007094T3 (cs)
EE (1) EE03857B1 (cs)
ES (1) ES2182133T3 (cs)
FR (1) FR15C0060I2 (cs)
HU (1) HU226616B1 (cs)
ID (1) ID21635A (cs)
IL (1) IL130449A0 (cs)
IS (1) IS1897B (cs)
MY (1) MY121982A (cs)
NO (1) NO327142B1 (cs)
NZ (1) NZ336027A (cs)
PL (1) PL190493B1 (cs)
PT (1) PT1007094E (cs)
RU (1) RU2205012C2 (cs)
SA (1) SA97180719B1 (cs)
SE (1) SE9604795D0 (cs)
SI (1) SI1007094T1 (cs)
SK (1) SK283137B6 (cs)
TR (1) TR199901412T2 (cs)
TW (1) TW522015B (cs)
UA (1) UA66779C2 (cs)
WO (1) WO1998028009A1 (cs)
ZA (1) ZA9711055B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
EP3978002A1 (en) 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
PE20221170A1 (es) * 2015-01-14 2022-07-25 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (cs) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Ａｔｐ凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge

Also Published As

Publication number Publication date
NO993067D0 (no) 1999-06-21
RU2205012C2 (ru) 2003-05-27
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
DK1007094T3 (da) 2002-10-28
CA2275153C (en) 2008-03-25
ES2182133T3 (es) 2003-03-01
AR010377A1 (es) 2000-06-07
IS1897B (is) 2003-10-20
EP1007094A1 (en) 2000-06-14
HK1026366A1 (en) 2000-12-15
IL130449A0 (en) 2000-06-01
MY121982A (en) 2006-03-31
NZ336027A (en) 2001-03-30
DE69714616D1 (de) 2002-09-12
EP1007094B1 (en) 2002-08-07
WO1998028009A1 (en) 1998-07-02
US6114313A (en) 2000-09-05
ZA9711055B (en) 1998-07-08
CN1240362A (zh) 2000-01-05
CZ300635B6 (cs) 2009-07-08
HUP0000572A3 (en) 2002-10-28
PT1007094E (pt) 2002-12-31
FR15C0060I1 (cs) 2015-10-23
EE9900260A (et) 2000-02-15
UA66779C2 (uk) 2004-06-15
PL334006A1 (en) 2000-01-31
PL190493B1 (pl) 2005-12-30
TR199901412T2 (xx) 1999-08-23
CN1121875C (zh) 2003-09-24
BR9713974A (pt) 2000-04-11
SK283137B6 (sk) 2003-03-04
ATE221787T1 (de) 2002-08-15
KR20000069598A (ko) 2000-11-25
HUP0000572A2 (hu) 2001-05-28
SE9604795D0 (sv) 1996-12-20
SI1007094T1 (en) 2003-02-28
SA97180719B1 (ar) 2006-05-13
EE03857B1 (et) 2002-10-15
BR9713974B1 (pt) 2010-02-23
AU758857B2 (en) 2003-04-03
TW522015B (en) 2003-03-01
NO327142B1 (no) 2009-05-04
JP2001507022A (ja) 2001-05-29
ID21635A (id) 1999-07-08
DE69714616T2 (de) 2003-04-03
CZ220199A3 (cs) 1999-11-17
CA2275153A1 (en) 1998-07-02
JP4488538B2 (ja) 2010-06-23
NO993067L (no) 1999-08-09
IS5064A (is) 1999-06-03
AU5351598A (en) 1998-07-17
HU226616B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
BR9611367A (pt) Formulação farmacêutic liofilizada estável
IT1276723B1 (it) Formulazioni di analoghi dell'insulina
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
DE69833464D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
IT1313549B1 (it) Formulazioni farmaceutiche a base di epotilone 3
IS4706A (is) Lyfjasamsetningar
NO20004345L (no) Farmasøytisk sammensetning
ID18352A (id) Komposisi-komposisi farmasi
FI950947L (fi) Oraalisesti annettavat farmaseuttiset formulaatiot
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
FI962952L (fi) Delta 12,13-iso-taksolianalogit, niiden antineoplastinen käyttö ja niitä sisältävät farmaseuttiset koostumukset
BR9610396A (pt) Formulação farmacêutica
FI991302A7 (fi) Parannetut farmaseuttiset koostumukset
PT868911E (pt) Formulacoes de rapamicina para administracao oral
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
PT1007094E (pt) Composicoes farmaceuticas compreendendo um analogo de nucleotido adequadas para liofilizacao
DE69614407D1 (de) Pharmazeutische zusammensetzungen
FR2742053B1 (fr) Compositions pharmaceutiques a base de mequitazine
LV12250A (lv) Farmaceitiskas kompozicijas uz diklofenaka bazes
ATE208364T1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
LV11727A (lv) Farmaceitiska kompozicija
PT941100E (pt) Composicoes farmaceuticas
FI973280L (fi) Farmaseuttinen koostumus
FI973230L (fi) Uusi farmaseuttinen formulaatio